ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Nutrition (OTCQB: ADIA) appointed Amy Dalrymple, MSN, APRN, FNP-C, to lead its new Regenerative Aesthetics Division at Adia Med of Winter Park.
Dalrymple brings 11 years in aesthetic medicine; services launch with an open house on March 30, 2026 and patient treatments begin April 6, 2026.
Appointments, consultations, and licensing inquiries are available via adianutrition.com and adiamed.com or by phone at 321-788-0850.
Adia Med (OTCQB: ADIA) relaunched its website with ZenChange Marketing to centralize clinical research information, study summaries, enrollment details, and social media management. A highlighted initiative is the Autism Stem Cell Clinical Study (NCT07304440), a 24-month investigational trial with active recruitment and a one-time participation cost of $12,000.
The interventional phase is anticipated to begin in May 2026. The organization emphasizes investigational status, informed consent, medical oversight, and participant safety while using a patient-pay model without grants or government funding.
Adia Nutrition (OTCQB: ADIA) announced that subsidiary Adia Med submitted a final revised protocol to the Institutional Review Board on March 3, 2026, for a lower back pain study of AdiaVita.
The trial is a single-blind, placebo-controlled IV study randomizing ~100 participants with a three-month initial treatment and a crossover phase; patient-pay remains $5,000 per participant.
Adia Nutrition (OTCQB: ADIA) said its Adia Med Winter Park clinic is expanding into cosmetic services and is interviewing a Nurse Practitioner for hair growth and aesthetic procedures as of February 24, 2026. New offerings include microneedling and targeted hair-restoration treatments using Adia's high-concentration stem cell products such as AdiaVita (advertised as 100 million stem cells and 3.5 trillion exosomes per unit).
The clinic invites qualified candidates and potential licensing partners to contact Adia Med for roles, services, and strategic collaborations at the Winter Park location.
Adia Nutrition (OTCQB: ADIA) said subsidiary Adia Med submitted a second clinical study for IRB review on February 16, 2026, testing AdiaVita delivered intravenously for lower back pain. The single-blind, placebo-controlled trial will randomize about 100 participants and uses a three-month treatment then crossover design.
Participation is patient-pay at $5,000 per patient, with no extra cost for the crossover phase. Enrollment begins after IRB approval and ClinicalTrials.gov acceptance.
Adia Nutrition (OTCQB: ADIA) plans to launch four to five new clinical studies in 2026, expanding work with Adia Vita (umbilical cord blood-derived stem cells and exosomes).
Key initiatives include an IRB-approved Autism Spectrum Disorder (NCT07304440) expansion to include 13-year-olds and a new study evaluating Adia Vita in rheumatoid arthritis. The company is pursuing multi-site IRB approvals and partnerships to support nationwide research and continues recruiting for its 24-month ASD trial following BeyondBound IRB approval in late 2025.
Adia Nutrition (OTCQB: ADIA) announced its Form 10 registration statement became effective on February 3, 2026, transitioning the company to full SEC reporting under Section 12(g). As a fully reporting registrant, Adia will file audited Form 10-Ks, quarterly 10-Qs, 8-Ks, and other disclosures.
The company said it is accelerating preparations for a potential NASDAQ Capital Market uplisting, named Dr. Brian Browning lead physician, noted an IRB-approved autism stem cell study now open worldwide, and referenced broad operational expansion in 2025.
Adia Nutrition (OTCQB: ADIA) named Dr. Brian L. Browning as lead physician for all orthopedic treatments and specialties at Adia Med in Winter Park, Florida, effective February 2, 2026.
Dr. Browning is board-certified in family and neuromusculoskeletal medicine, leads non-surgical regenerative care, and will oversee stem cell, PRP, ultrasound-guided injections, and related orthopedic services integrated with Adia Med's AdiaVita products.
Adia Nutrition (OTCQB: ADIA) announced a documentary documenting wrestler Jeff Sciullo's June 2025 tricep injury and recovery using Adia Med's AdiaVita stem cell protocol. Filmed for The Dr. Asa Network, the film highlights doses delivering >100 million umbilical cord stem cells and >3 trillion exosomes per dose and will air February–March 2026 across radio, TV, podcast, and social platforms.
The company invites clinic licensing and strategic partnerships to expand access to its regenerative therapies.
Adia Nutrition (OTCQB: ADIA) announced details of an IRB-approved, 24-month randomized crossover study (NCT07304440) testing umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) in ~100 children age 3-12 with confirmed autism spectrum disorder.
The interventional phase delivers three monthly AdiaVita infusions plus glutathione in the active arm; the comparator arm begins with glutathione alone and may crossover later. Primary outcome is change in ATEC scores with close safety monitoring. A one-time $12,000 participation fee covers both phases and all study activities. Recruitment is active at Adia Med in Winter Park, Florida, open to U.S. and international families who can attend visits.